In CRC, curcumin has been combined with 5-FU-based therapies in different models where it has been demonstrated to potentiate the chemotherapy effect and reverse chemoresistance through diverse pathways, including TS regulation in colon cancer cell lines, due to its inhibition of the nuclear translocation of NFκB and, consequently, the decrease in E2F1 transcription factor, a promoter of cell proliferation [85,86]. This evidence concerns the gene TYMS and colorectal carcinoma.